NEO NeoGenomics, Inc. Maintained: Cowen Buy, William Blair Market Perform Mar 2026

On March 16, 2026 the NEO analyst rating update showed Cowen & Co. kept Buy and William Blair kept Market Perform. Both firms published their verdicts during morning coverage, with Cowen citing reimbursements that could lift 2026 revenue by 3–4%, and William Blair noting a recent positive catalyst for the story. The two actions were both marked as Maintained and produced small intraday moves: Cowen coverage coincided with a 0.12% ($0.01) change and William Blair with a 0.24% ($0.02) change. Meyka AI rates NEO with a grade of B and tracks these shifts in real time.

NEO analyst rating summary

On March 16, 2026 two major firms issued maintained ratings for NeoGenomics, Inc. (NEO): Cowen & Co. reiterated Buy and William Blair reiterated Market Perform. Both notes were published within 35 minutes of each other and referenced different catalysts and risks. Neither update included a new price target.

Cowen & Co. maintains Buy on NEO

At 9:39 AM ET on March 16, 2026 TD Cowen reiterated a Buy rating, highlighting that reimbursement shifts could drive 2026 revenue 3–4% higher. Cowen left its view unchanged and framed the stock as benefiting from improving reimbursement dynamics. The action registered a 0.12% ($0.01) intraday move for the stock. Read the Cowen note source.

William Blair maintains Market Perform on NEO

At 10:14 AM ET on March 16, 2026 William Blair reiterated Market Perform, citing a ‘much-needed positive catalyst’ but still signaling limited near-term upside. William Blair left its rating intact while noting the catalyst does not yet change the medium-term revenue or margin outlook. The firm’s note correlated with a 0.24% ($0.02) intraday move. See the William Blair note source.

Investor implications of these NEO rating actions

Maintained ratings tell investors that analysts see no near-term reason to change conviction given current data. Cowen’s stance suggests upside if reimbursements accelerate revenue, while William Blair’s stance advises caution on near-term returns. Investors should weigh these views against NEO’s fundamentals and market-cap of $213,930,176.

Historical analyst coverage and context for NEO

Analyst coverage of NeoGenomics has mixed sentiment historically, oscillating between cautious holds and selective buys as reimbursement and diagnostic adoption evolve. Recent maintained calls show analysts are watching catalysts rather than revising base cases. These March 16, 2026 notes continue a pattern of measured, catalyst-driven guidance rather than aggressive revisions.

Meyka grade, next steps, and how to use the NEO analyst rating

Meyka AI rates NEO with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Use the grade as one input alongside analyst notes, earnings, and reimbursement trends when sizing positions. For live updates and the stock page see Meyka NEO page.

Final Thoughts

Both March 16, 2026 notes kept ratings unchanged, leaving the near-term story intact. Cowen’s maintained Buy emphasizes potential upside from reimbursement improvements that could lift 2026 revenue by 3–4%. William Blair’s maintained Market Perform flags that the recent catalyst improves sentiment but does not alter its medium-term view. Investors should treat these maintained calls as confirmation that analysts want more visible revenue or margin momentum before changing convictions. Meyka AI’s real-time tracking and a B grade for NEO provide context, but past ratings and grades are not guarantees and do not constitute investment advice.

Key takeaways: the two maintained ratings show divergent risk-reward views while neither firm supplied a new price target. For investors that prefer upside exposure tied to reimbursements, Cowen’s note supports a constructive stance. For risk-averse investors, William Blair’s view suggests patience until clearer top-line or margin improvements appear.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.